OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline DOI Creative Commons
Nicola d’Avanzo, Donatella Paolino, Antonella Barone

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 2, 2024

Abstract Cerebrovascular impairment still represents one of the main causes death worldwide with a mortality rate 5.5 million per year. Furthermore, disability 50% surviving patients factor both high social impact and costs for long periods time national healthcare systems. For these reasons, efficacious clinical treatment suffering brain ischemic stroke is medical need. To this aim, liposome nanomedicine having monosialic ganglioside type 1 (GM1) between its constituent bearing OX26 (an anti-transferrin receptor antibody) was prepared by entrapping CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip), characterized tested in vivo on an rat model. CDP-choline/OX26Lip were freeze thaw followed extrusion through polycarbonate filters, thus achieving ~80 nm mean size homogeneous distribution. It demonstrated that showed suitable stability presence human serum. also pharmacokinetic profile, 30.0±4.2 % administered dose blood stream 12 h after systemic administration. The post-ischemic therapeutic effect better than CDP-choline/Lip, showing significant greater survival re-perfused rats, i.e. 96% 78% 8 days, respectively. significantly decreased peroxidation almost 5-fold compared to as expressed amount conjugated dienes,i.e. 13.9 ± 1.1 3.1 0.8 mmol/mg proteins, increased could be attributed improved accumulation encapsulated delivered OX26-conjugated GM1-liposomes. Therefore, may represent strategy reassessment line option events caused stroke, responding needs.

Language: Английский

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline DOI Creative Commons
Nicola d’Avanzo, Donatella Paolino, Antonella Barone

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 2, 2024

Abstract Cerebrovascular impairment still represents one of the main causes death worldwide with a mortality rate 5.5 million per year. Furthermore, disability 50% surviving patients factor both high social impact and costs for long periods time national healthcare systems. For these reasons, efficacious clinical treatment suffering brain ischemic stroke is medical need. To this aim, liposome nanomedicine having monosialic ganglioside type 1 (GM1) between its constituent bearing OX26 (an anti-transferrin receptor antibody) was prepared by entrapping CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip), characterized tested in vivo on an rat model. CDP-choline/OX26Lip were freeze thaw followed extrusion through polycarbonate filters, thus achieving ~80 nm mean size homogeneous distribution. It demonstrated that showed suitable stability presence human serum. also pharmacokinetic profile, 30.0±4.2 % administered dose blood stream 12 h after systemic administration. The post-ischemic therapeutic effect better than CDP-choline/Lip, showing significant greater survival re-perfused rats, i.e. 96% 78% 8 days, respectively. significantly decreased peroxidation almost 5-fold compared to as expressed amount conjugated dienes,i.e. 13.9 ± 1.1 3.1 0.8 mmol/mg proteins, increased could be attributed improved accumulation encapsulated delivered OX26-conjugated GM1-liposomes. Therefore, may represent strategy reassessment line option events caused stroke, responding needs.

Language: Английский

Citations

0